Use of benzodiazepine and risk of cancer: A meta-analysis of observational studies.
Several observational epidemiological studies have reported inconsistent results on the association between the use of benzodiazepine and the risk of cancer. We investigated the association by using a meta-analysis. We searched PubMed, EMBASE, and the bibliographies of relevant articles to locate additional publications in January 2016. Three evaluators independently reviewed and selected eligible studies based on predetermined selection criteria. Of 796 articles meeting our initial criteria, a total of 22 observational epidemiological studies with 18 case-control studies and 4 cohort studies were included in the final analysis. Benzodiazepine use was significantly associated with an increased risk of cancer (odds ratio [OR] or relative risk [RR] 1.19; 95% confidence interval 1.16-1.21) in a random-effects meta-analysis of all studies. Subgroup meta-analyses by various factors such as study design, type of case-control study, study region, and methodological quality of study showed consistent findings. Also, a significant dose-response relationship was observed between the use of benzodiazepine and the risk of cancer (p for trend <0.01). The current meta-analysis of observational epidemiological studies suggests that benzodiazepine use is associated with an increased risk of cancer.
Department of Family Medicine, MyongJi Hospital, 14-55 Hwasu-ro, Deokyang-gu, Goyang, Gyeonggi-do, 10475, Republic of Korea.|Department of Family Medicine, School of Medicine, Yonsei University, 50-1 Yonsei-ro, Seodaemoon-gu, Seoul, 03722, Republic of Korea.
Hong-Bae
HB
Kim
Department of Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do, 10408, Republic of Korea.|Molecular Epidemiology Branch, Division of Cancer Epidemiology and Prevention, Research Institute, National Cancer Center, Goyang, Republic of Korea.|Department of Family Medicine and Center for Cancer Prevention and Detection, Hospital, National Cancer Center, Goyang, Republic of Korea.
Seung-Kwon
SK
Myung
Department of Family Medicine, School of Medicine, Yonsei University, 50-1 Yonsei-ro, Seodaemoon-gu, Seoul, 03722, Republic of Korea.|Department of Family Medicine, Wonju Severance Christian Hospital, 20 Ilsan-ro, Wonju, Gangwon-do, 220-701, Republic of Korea.
Yon Chul
YC
Park
Department of Family Medicine, School of Medicine, Yonsei University, 50-1 Yonsei-ro, Seodaemoon-gu, Seoul, 03722, Republic of Korea.|Department of Family Medicine, Yongin Severance Hospital, 225 Gumhak-ro, Cheoin-gu, Yongin, Gyeonggi-do, 17046, Republic of Korea.
Byoungjin
B
Park
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001569:Benzodiazepines / Q000009:adverse effects*; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000139:chemically induced*; D064887:Observational Studies as Topic; D012107:Research Design; D012306:Risk; D018570:Risk Assessment; D055815:Young Adult
D001569:Benzodiazepines
benzodiazepine; cancer; meta-analysis; observational study